NUVB — Nuvation Bio Cashflow Statement
0.000.00%
- $1.70bn
- $1.38bn
- $62.90m
Annual cashflow statement for Nuvation Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -86.8 | -104 | -75.8 | -568 | -205 |
| Depreciation | |||||
| Non-Cash Items | 13.7 | 11.3 | 7.04 | 449 | 41.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.79 | -3.45 | 0.54 | -12.5 | -12 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -68.2 | -96.1 | -68 | -130 | -173 |
| Capital Expenditures | -0.282 | -0.37 | -0.069 | -0.162 | -8.35 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -454 | 63.8 | 8.99 | 123 | 108 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -455 | 63.5 | 8.92 | 123 | 99.5 |
| Financing Cash Flow Items | 625 | 0 | — | — | 143 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 626 | 1.33 | 0.628 | 0.331 | 203 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 103 | -31.3 | -58.5 | -6.93 | 128 |